Molecular techniques for the personalised management of patients with chronic myeloid leukaemia

Por Alikian, Mary, Gale, Robert Peter, Apperley, Jane F, Foroni, Letizia
Publicado no Biomol Detect Quantif (2017)

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

Por Milojkovic, Dragana, Ibrahim, Amr, Reid, Alistair, Foroni, Letizia, Apperley, Jane, Marin, David
Publicado em 2012

Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis

Por Williams, Christopher KO, Foroni, Letizia, Luzzatto, Lucio, Saliu, Idris, Levine, Arthur, Greaves, Mel F
Publicado no Ecancermedicalscience (2014)

Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients

Por Davies, Andrea, Rodriguez-Vicente, Ana Eugenia, Austin, Gemma, Loaiza, Sandra, Foroni, Letizia, Clark, Richard E, Pirmohamed, Munir
Publicado no Sci Rep (2020)

Recurrent histone mutations in T‐cell acute lymphoblastic leukaemia

Por Collord, Grace, Martincorena, Inigo, Young, Matthew D., Foroni, Letizia, Bolli, Niccolo, Stratton, Michael R., Vassiliou, George S., Campbell, Peter J., Behjati, Sam
Publicado no Br J Haematol (2018)

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

Por Kuwabara, Aya, Babb, Anna, Ibrahim, Amr, Milojkovic, Dragana, Apperley, Jane, Bua, Marco, Reid, Alistair, Foroni, Letizia, Rezvani, Katayoun, Goldman, John, Marin, David
Publicado em 2010

The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma

Por Cook, Lucy B., Melamed, Anat, Niederer, Heather, Valganon, Mikel, Laydon, Daniel, Foroni, Letizia, Taylor, Graham P., Matsuoka, Masao, Bangham, Charles R. M.
Publicado em 2014

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Por Claudiani, Simone, Apperley, Jane F., Gale, Robert Peter, Clark, Richard, Szydlo, Richard, Deplano, Simona, Palanicawandar, Renuka, Khorashad, Jamshid, Foroni, Letizia, Milojkovic, Dragana
Publicado no Haematologica (2017)

Acaps Are Arf6 Gtpase-Activating Proteins That Function in the Cell Periphery

Por Jackson, Trevor R., Brown, Fraser D., Nie, Zhongzhen, Miura, Koichi, Foroni, Letizia, Sun, Jianlan, Hsu, Victor W., Donaldson, Julie G., Randazzo, Paul A.
Publicado em 2000

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Por Milojkovic, Dragana, Apperley, Jane F., Gerrard, Gareth, Ibrahim, Amr R., Szydlo, Richard, Bua, Marco, Reid, Alistair, Rezvani, Katayoun, Foroni, Letizia, Goldman, John, Marin, David
Publicado no Blood (2012)

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?

Por Gall, Tamara M.H., Gerrard, Gareth, Frampton, Adam E., Castellano, Leandro, Ahmad, Raida, Habib, Nagy, Spalding, Duncan, Pai, Madhava, Foroni, Letizia, Jiao, Long R.
Publicado no Oncotarget (2019)

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

Por Claudiani, Simone, Gatenby, Aoife, Szydlo, Richard, Nesr, George, Abulafia, Adi Shacham, Palanicawandar, Renuka, Nteliopoulos, Georgios, Khorashad, Jamshid, Foroni, Letizia, Apperley, Jane F., Milojkovic, Dragana
Publicado no Haematologica (2019)

The status of epidermal growth factor receptor in borderline ovarian tumours

Por Showeil, Rania, Romano, Claudia, Valganon, Mikel, Lambros, Maryou, Trivedi, Pritesh, Van Noorden, Susan, Sriraksa, Ruethairat, El-Kaffash, Dalal, El-Etreby, Nour, Natrajan, Rachael, Foroni, Letizia, Osborne, Richard, El-Bahrawy, Mona
Publicado no Oncotarget (2016)

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Por Ibrahim, Amr R., Paliompeis, Christos, Bua, Marco, Milojkovic, Dragana, Szydlo, Richard, Khorashad, Jamshid S., Foroni, Letizia, Reid, Alistair, de Lavallade, Hugues, Rezvani, Katayoun, Dazzi, Francesco, Apperley, Jane F., Goldman, John M., Marin, David
Publicado no Blood (2010)

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

Por Khorashad, Jamshid Sorouri, Wagner, Simon, Greener, Liat, Marin, David, Reid, Alistair, Milojkovic, Dragana, Patel, Hetal, Willimott, Shaun, Rezvani, Katy, Gerrard, Gareth, Loaiza, Sandra, Davis, John, Goldman, John, Melo, Junia, Apperley, Jane, Foroni, Letizia
Publicado em 2009

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Por Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.
Publicado no Blood (2008)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Por Nteliopoulos, Georgios, Bazeos, Alexandra, Claudiani, Simone, Gerrard, Gareth, Curry, Edward, Szydlo, Richard, Alikian, Mary, Foong, Hui En, Nikolakopoulou, Zacharoula, Loaiza, Sandra, Khorashad, Jamshid S., Milojkovic, Dragana, Perrotti, Danilo, Gale, Robert Peter, Foroni, Letizia, Apperley, Jane F.
Publicado no Haematologica (2019)

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Por Milojkovic, Dragana, Nicholson, Emma, Apperley, Jane F., Holyoake, Tessa L., Shepherd, Pat, Drummond, Mark W., Szydlo, Richard, Bua, Marco, Foroni, Letizia, Reid, Alistair, Khorashad, Jamshid S., de Lavallade, Hugues, Rezvani, Katy, Paliompeis, Christos, Goldman, John M., Marin, David
Publicado em 2010

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibito...

Por Marin, David, Ibrahim, Amr R., Lucas, Claire, Gerrard, Gareth, Wang, Lihui, Szydlo, Richard M., Clark, Richard E., Apperley, Jane F., Milojkovic, Dragana, Bua, Marco, Pavlu, Jiri, Paliompeis, Christos, Reid, Alistair, Rezvani, Katayoun, Goldman, John M., Foroni, Letizia
Publicado no J Clin Oncol (2012)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Por Fielding, Adele K., Rowe, Jacob M., Buck, Georgina, Foroni, Letizia, Gerrard, Gareth, Litzow, Mark R., Lazarus, Hillard, Luger, Selina M., Marks, David I., McMillan, Andrew K., Moorman, Anthony V., Patel, Bella, Paietta, Elisabeth, Tallman, Martin S., Goldstone, Anthony H.
Publicado em 2014